Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
Am J HematolJul 28, 2026 (epub)
Yifan Han, Ning Lin, Jinghang Xu et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, randomized, double-blind, placebo-controlled phase III trial evaluated recombinant human thrombopoietin (rhTPO) in 120 adults with chronic liver disease-related thrombocytopenia undergoing elective invasive procedures. The study found that 85.0% of patients receiving rhTPO achieved sustained platelet counts ≥50 × 10^9/L compared to 12.5% in the placebo group (p < 0.0001).
Key findings
- 85.0% of rhTPO patients achieved sustained platelet counts ≥50 × 10^9/L vs 12.5% in placebo (p < 0.0001).
- Platelet transfusion was avoided in 92.5% of rhTPO patients compared to 25.0% in placebo (p < 0.0001).
- Median duration of platelet counts ≥50 × 10^9/L was 21.0 days for rhTPO vs 3.0 days for placebo (p = 0.0007).
Why it matters
The findings suggest that rhTPO significantly reduces the need for platelet transfusions in patients with chronic liver disease and thrombocytopenia, potentially improving the safety and feasibility of invasive procedures in this population.